ESC 365 - Influence of achieved LVEF on efficacy of dapagliflozin in patients with heart failure with improved ejection fraction: the DELIVER trial

HFA Premium Access

Influence of achieved LVEF on efficacy of dapagliflozin in patients with heart failure with improved ejection fraction: the DELIVER trial

Session: Chronic heart failure - epidemiology, prognosis, outcome 3

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor S. Siqueira (Boston, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Sara Rodrigues De Oliveira Siqueira

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

0 follower

6 more presentations in this session

Neutrophil-to-lymphocyte ratio (NLR) and mortality in heart failure: analysis of population-level data

Speaker: Mr M. Morsy (Glasgow, GB)

Pain and anxiety in heart failure - findings from FINEARTS-HF

Speaker: Doctor M. Yang (Nanjing, CN)

Prognostic stratification of acute heart failure patients using the 3C-HF SCORE: short vs long term prediction

Speaker: Doctor M. Gori (Bergamo, IT)

Health-related quality of life in women versus men with heart failure across the spectrum of LVEF

Speaker: Doctor M. Yang (Nanjing, CN)

Machine learning does not improve risk prediction in heart failure in comparison to the PREDICT-HF model: derivation and validation in PARADIGM-HF and ATMOSPHERE

Speaker: Doctor A. Talebi (Glasgow, GB)

Access the full session

Chronic heart failure - epidemiology, prognosis, outcome 3

Speakers: Doctor S. Siqueira, Mr M. Morsy, Doctor M. Yang, Doctor M. Gori, Doctor M. Yang...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources